A retrospective evaluation of lomustine (CeeNU) in 32 treatment naïve cats with intermediate to large cell gastrointestinal lymphoma (2006-2013).

Abstract

Multi-drug chemotherapy protocols for feline lymphoma have demonstrated variable efficacy and tolerability. In phase I trials, lomustine has demonstrated efficacy for cats with lymphoma though its use for treatment naïve feline intermediate/large cell gastrointestinal (GI) lymphoma remains unknown. This study evaluated the efficacy and tolerability of lomustine for the treatment of feline GI lymphoma. Thirty-two cats with histologically or cytologically confirmed intermediate/large cell GI lymphoma were evaluated retrospectively. Factors assessed included clinical signs, hematologic/biochemical parameters and use of l-asparaginase at induction. A response rate of 50% (16/32), with median duration of response of 302 days (range 64-1450 days), was found. Median progression-free interval was 132 days (range 31-1450 days), with overall median survival time of 108 days (range 4-1488 days). History of hyporexia, presence of anaemia and dose of lomustine were significantly associated with progression-free survival. Overall, lomustine is a well-tolerated and effective treatment for feline GI lymphoma.

• Authors: S E Rau, K E Burgess
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 15 Issue 3 Pg. 1019-1028 (Sep 2017) ISSN: 1476-5829 [Electronic] England
• PMID: 27277825 (Publication Type: Journal Article)
• Copyright: © 2016 John Wiley & Sons Ltd.

Chemical References

• Antineoplastic Agents, Alkylating
• Lomustine

Topics

• Animals
• Antineoplastic Agents, Alkylating (therapeutic use)
• Cat Diseases (drug therapy)
• Cats
• Female
• Gastrointestinal Neoplasms (drug therapy, veterinary)
• Lomustine (therapeutic use)
• Lymphoma (drug therapy, veterinary)
• Male
• Retrospective Studies
• Treatment Outcome